Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors for hematologic cancers.

R R Misra1, P F Pinsky, S Srivastava

  • 1Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, Maryland, USA.

Hematology/Oncology Clinics of North America
|August 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort.

Cancer epidemiology·2016
Same author

Smoking associated with malignancy, hypertension, chronic obstructive pulmonary disease and concurrent coronary artery disease: report of nine cases.

The Indian journal of chest diseases & allied sciences·2008
Same author

Characterization of a new isolate of Pseudomonas fluorescens strain Psd as a potential biocontrol agent.

Letters in applied microbiology·2008
Same author

Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

Journal of clinical pathology·2008
Same author

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Oncogene·2008
Same author

Regulation of oxidative stress-mediated apoptosis by diallyl sulfide in DMBA-exposed Swiss mice.

Human & experimental toxicology·2008
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

This review explores the molecular basis of blood cancers and identifies key prognostic factors. It highlights specific molecular biomarkers and statistical methods for assessing their predictive value in hematologic malignancies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Hematologic cancers encompass a range of malignancies affecting blood, bone marrow, and lymph nodes.
  • Understanding prognostic factors is crucial for tailoring treatment strategies and predicting patient outcomes.
  • Advances in molecular biology have revealed complex mechanisms underlying these diseases.

Purpose of the Study:

  • To review the molecular biology of hematologic cancers.
  • To discuss current knowledge of prognostic factors in these cancers.
  • To present methods for evaluating the utility of prognostic factors.

Main Methods:

  • Literature review of molecular biology in hematologic cancers.
  • Identification and discussion of molecular biomarkers with prognostic potential.

Related Experiment Videos

  • Overview of quantitative and statistical approaches for prognostic factor evaluation.

    • Main Results:

    • The molecular landscape of hematologic cancers is complex and varied.
    • Several molecular biomarkers show promise for predicting disease progression and patient survival.
    • Statistical methods are essential for validating the clinical usefulness of prognostic factors.

    Conclusions:

    • Molecular insights are transforming the understanding of hematologic cancers.
    • Prognostic factors, particularly molecular biomarkers, are vital for personalized medicine in hematology.
    • Rigorous statistical evaluation is necessary to integrate new prognostic markers into clinical practice.